secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-04-22T23:59:59+00:00
Accession:  0000950170-25-056480
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health briefed White House and FDA on TLR5 candidates and ncVNS; positive interest noted
--------------------------------------------------------------------------------

- On April 17, 2025, briefed White House senior leadership on Entolimod for acute radiation syndrome and need for advanced treatments.
- Met with FDA to discuss expedited pathways for Entolimod, Entolasta (second-gen TLR5 agonist), and non-invasive cervical VNS technology.
- Previous U.S. government funding from BARDA, NASA, DTRA, DoD, and Army for TLR5 program highlighted.
- Positive interest in military/defense applications; FDA explored breakthrough device designations for ncVNS after clinical work.
- CEO Jennifer Ernst expects continued discussions as programs progress toward potential FDA approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025056480/0000950170-25-056480-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025056480/tivc-20250422.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-056480

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer